Established in 2023 and headquartered in California, A venture capital firm invests in Seed-Series B companies in pre-clinical and clinical stages. The firm’s current portfolio contains USA based companies, and they are looking to expand their investments into European companies. The firm is investing from its first fund valued at $100M. Depending on investment stage, the firm will invest between $1M-$10M. The firm is open to global investments.
The firm is focused on investing in neuroscience-based technology companies and will invest in medical devices and diagnostics. The firm does not invest in therapeutic (drug) companies. Indications of interest are focused on brain disorders, with a particular interest in neurodegenerative, neurodevelopmental, and neuropsychiatric conditions including Parkinson’s disease, autism spectrum disorder, and bipolar disorder. The firm applies a broad definition to the technology solution space for these clinical conditions to include therapeutic medical devices (non-invasive and invasive), data platforms, imaging platforms, drug-device combinations, therapy enabling tools, and research tools.
The firm is open to leading or co-investing. The firm prefers, however, to lead and will generally prefer a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
Life Science Nation (LSN) presents the Program Guide for the inaugural RESI Europe conference in Barcelona, taking place in person on June 17 at the Hilton Diagonal Mar Barcelona, followed by two virtual partnering days on June 18-19. This hybrid event connects early-stage life sciences innovators with global investors.
Highlights include the Innovator’s Pitch Challenge showcasing over 40 cutting-edge companies, expert panel discussions on industry trends, interactive workshops, and an exhibitor showcase.
Check out the guide below and join the forefront of European life sciences investment and partnership. Don’t miss this game-changing opportunity – there is still time to register.
ApexBrasil and Abiquifi, government and pharma organizations in Brazil, worked together to hand-pick 10 startups to represent the amazing Brazilian innovation ecosystem in the life sciences at BIO this week. Brazil is making an effort to bring their technologies abroad, and each of the companies attending have either established or are establishing a US presence in an effort to expand.
Life Science Nation (LSN) partnered with this group to help the companies get ready for BIO, with 5 virtual sessions outlining how to position themselves with their story and their marketing collateral and how to maximize their partnering experience. This was followed by two in person days, with a day of pitch practice followed by a ‘Shark Tank’ session of the companies pitching to a live audience. Check out the participating companies below!
Aptah Biosciences: We are developing the first and only compound that corrects multiple faulty RNAs (coding and noncoding) and resulting toxic proteins at the same time.
Bioptamers: Development of ADC (antibody drug conjugates)-like target cancer therapies using aptamers instead of antibodies.
Gen-t: Genomics data platform that leverages genetic diversity of the Brazilian population to accelerate biomedical research and development of life-science companies.
miRscience Therapeutics: RNA therapies focused on age-related diseases. The first indication is sarcopenia.
Naiad: AI/ML based small molecule therapeutics design and development focused on GPCRs (oncology and psychiatry).
Peptidus Biotech: AI/ML based development of bioactive peptides for animal and human applications.
Science Biotech: Biotech specialized in the development of cardiovascular disease focused assets
Vyro Biotherapeutics: The first oncolytic therapy based on genetically modified zika vírus. Glioblastoma is the first indication.
Wecare: Develops and commercializes innovative functional skin products to oncologic patients.
XenoBR: Development of genetically engineered pigs that their organs are suitable for human transplantation.
Life Science Nation (LSN) staff hear daily from the early-stage companies that cash is king and that they do not have the funds to travel across the globe to attend partnering events… a very bleak picture. On the other hand, LSN sees that many countries and regions with life science innovation ecosystems are funding and subsidizing costs for select cohorts of startups.
Cash for startups surfaces when government, academia and industry collaborate to create funded programs. Thus, we have The Tales of Two Cities. The money goes to the lucky few considered the best of the best, and the majority are left fending for themselves. Welcome to the golden age of life science; thousands of amazing startups with game-changing technologies are forced to figure it out or perish, accounting for a 90%+ failure rate.
The world of the startup CEO, devoid of the elite status moniker, is a constant battle for funds. They resort to every possible means: seeking help from friends and family, applying for more credit cards and even getting a second mortgage. They rely on spouses or partners to pay the bills, work two jobs, write grants, hustle consulting gigs, and spend each day in a 24/7 scramble to survive. The harsh reality is that a small percentage of early-stage companies are being selected for funding, a small percentage are dancing as fast as they can to make ends meet, and the rest are half in and half out of the game because of the cash commitment dynamic.
Investors typically consider 800 startups over a year but only invest in a few. Conversely, startups need to target 800 partners to get a lead investor and a few LPs…thus the 800:3 rule.
LSN has the lowest-cost partnering platform that assists startups in reaching the crucial 800 targets; LSN RESI partnering conferences like RESI Europe. June 17-19, allow more early-stage companies into the game. RESI Boston, September25-27 and RESI JPM, in January round out the RESI conference series. These events offer opportunities for startups to connect with potential investors and partners globally, increasing their chances of securing funding.
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
The RESI Europe, Innovator’s Pitch Challenge (IPC) finalists are in! This exciting event will feature 11 sessions where finalist companies pitch their innovative ideas to a panel of investors and industry experts. Additionally, each company will showcase a posterboard in the RESI exhibit hall throughout the conference, allowing attendees to learn more about their offerings.
Innovator’s Pitch Challenge Companies At RESI Europe 2024
All RESI attendees will receive 5 pieces of “RESI Cash” to vote for their favorite companies. The 3 companies with the most votes will be announced at the end of RESI, receiving a prize and a feature in the RESI newsletter. This is a valuable opportunity for participating startups to put themselves out there, actively fundraising and meeting conference attendees, half of whom are investors.
The participating companies are listed below. If you plan to attend RESI Europe, be sure to check out their pitches and poster boards. If you’re interested in seeing these presentations and meeting with the companies one-on-one, you can register for the event here.
LSN’s RESI Conference is coming to Barcelona, Spain for the first time on June 17th at The Hilton Diagonal Mar. We are excited to announce the Digital Health Investor Panel. LSN has brought together global investors of varied backgrounds to discuss recent trends, common mistakes, advice, and more, with a focus to push digital health innovations forward. Look below for our Digital Health panelists.
RESI Europe Digital Health Panel Speakers
Moderator
David Cole Venture Partner Springhood Ventures
Christian Bjelland Managing Director, Capital Network & Global Development
Redesign Healt
Jordi Ferrer Healthcare Investment Director
Ship2B Ventures
Tom Gibbs Director Debiopharm Innovation Fun
Ignasi Heras General Partner CRB Inverbio
Carsten Laue Managing Partner M2Car
The investor panels are a hallmark of the RESI Conference series where attendees can look forward to a comprehensive array of panel discussions. These panels will delve into a wide range of topics, from specific investor types providing a stimulating environment for startups and investors to explore potential funding opportunities. Each panel will be moderated by industry experts with deep domain knowledge, offering meaningful insights and fostering engaging discussions. Through this multifaceted approach, LSN strives to create a dynamic platform that facilitates networking, knowledge sharing, and the exploration of potential partnerships between startups and investors.
Greg Mannix VP of European Sales at Life Science Nation is also CEO of Novaurum Biosciences and has attended 15 life science partnering conferences in the last two years as a startup CEO. After this extensive experience, he shares his insights on whether these events are worth the investment and what constitutes a good return on investment (ROI) in terms of outcomes and the number of investor meetings secured. Attending partnering conferences can be a significant investment for life science companies, especially startups and early-stage firms. Mannix emphasizes the importance of carefully evaluating the potential ROI before committing resources.
A successful conference should yield tangible outcomes, such as securing funding, establishing strategic partnerships, or gaining valuable industry insights. Mannix suggests that a good ROI can be measured by the number of quality investor meetings scheduled during the event. “For a conference to be considered successful, I aim to secure at least 10-15 meetings with potential investors or partners that align with our company’s goals and stage of development,” Mannix explains. “These meetings should lead to meaningful discussions and potential collaborations or investment opportunities.”
To maximize the value of partnering events, Mannix recommends a strategic approach. Thorough preparation, targeted networking, and effective follow-up are crucial. “It’s essential to research the attending investors and companies beforehand and strategically request meetings with those that are the best fit,” Mannix advises. “During the event, actively participate in panel discussions, workshops, and networking sessions to gain industry insights and make valuable connections.” Mannix also emphasizes the importance of prompt and professional follow-up after the conference. “Timely and personalized communication with the contacts made during the event can significantly increase the chances of securing partnerships or investments,” he adds.
RESI Europe is taking place in Barcelona on June 17 (in-person) and June 18-19 (virtual). This conference aims to connect startups and early-stage investors, offering a platform for fundraising and partnership opportunities. With a 1:1 ratio of investors to companies and over 250 life science investors in attendance, RESI Europe promises to maximize the number of meetings and potential collaborations. Partnering has opened, and you can register today to secure meeting slots while they are still available.
While life science partnering conferences require an investment, they can provide substantial returns in terms of funding, partnerships, and industry insights when approached strategically. By carefully evaluating the potential ROI, preparing thoroughly, and actively engaging in networking and follow-up, companies can maximize the value of these events and propel their growth in the life science industry.
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
Next Phase Newsletter 